Literature DB >> 20400523

SOD and inhaled nitric oxide normalize phosphodiesterase 5 expression and activity in neonatal lambs with persistent pulmonary hypertension.

Kathryn N Farrow1, Satyan Lakshminrusimha, Lyubov Czech, Beezly S Groh, Sylvia F Gugino, Jonathan M Davis, James A Russell, Robin H Steinhorn.   

Abstract

Phosphodiesterase 5 (PDE5) and soluble guanylate cyclase (sGC) are key regulators of cGMP and pulmonary vascular tone. We sought to determine the impact of mechanical ventilation with O(2) with or without inhaled nitric oxide (iNO) or recombinant human Cu/Zn SOD (rhSOD) on sGC, PDE5, and cGMP in the ovine ductal ligation model of persistent pulmonary hypertension of the newborn (PPHN). PPHN lambs were ventilated with 100% O(2) for 24 h alone or combined with either inhalation of 20 parts per million (ppm) iNO continuously or a single intratracheal dose of rhSOD (5 mg/kg). Ventilated PPHN lambs were compared with PPHN fetuses, control fetuses, and 1-day-old spontaneously breathing lambs (1DSB). In the small pulmonary arteries of 1DSB lambs, sGC expression increased, PDE5 expression decreased, and cGMP concentrations increased relative to fetal levels. In PPHN lambs ventilated with 100% O(2), sGC activity increased to levels comparable with 1DSB levels. However, PDE5 expression and activity increased, and cGMP levels remained at fetal levels. Addition of either iNO or rhSOD decreased PDE5 expression and activity in PPHN lambs and increased cGMP levels to levels comparable with 1DSB lambs. These data suggest that ventilation of PPHN lambs with 100% O(2) impairs cGMP-mediated vasodilation in part due to increased PDE5 expression and activity. The addition of either iNO or rhSOD normalized PDE5 and cGMP levels. Thus therapies designed to decrease PDE5 and increase cGMP, such as iNO and rhSOD, may prove useful in the treatment of PPHN in newborn infants.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20400523      PMCID: PMC2904095          DOI: 10.1152/ajplung.00309.2009

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  50 in total

1.  Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep.

Authors:  Philippe Deruelle; Theresa R Grover; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-06-17       Impact factor: 5.464

2.  Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message.

Authors:  K A Hanson; F Burns; S D Rybalkin; J W Miller; J Beavo; W R Clarke
Journal:  Am J Respir Crit Care Med       Date:  1998-07       Impact factor: 21.405

3.  Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group.

Authors:  J D Roberts; J R Fineman; F C Morin; P W Shaul; S Rimar; M D Schreiber; R A Polin; M S Zwass; M M Zayek; I Gross; M A Heymann; W M Zapol
Journal:  N Engl J Med       Date:  1997-02-27       Impact factor: 91.245

4.  Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure.

Authors: 
Journal:  N Engl J Med       Date:  1997-02-27       Impact factor: 91.245

5.  Dipyridamole potentiates pulmonary vasodilation induced by acetylcholine and nitric oxide in the ovine fetus.

Authors:  J W Ziegler; D D Ivy; J J Fox; J P Kinsella; W R Clarke; S H Abman
Journal:  Am J Respir Crit Care Med       Date:  1998-04       Impact factor: 21.405

6.  Ventilation and oxygenation induce endothelial nitric oxide synthase gene expression in the lungs of fetal lambs.

Authors:  S M Black; M J Johengen; Z D Ma; J Bristow; S J Soifer
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

7.  Pulmonary soluble guanylate cyclase, a nitric oxide receptor, is increased during the perinatal period.

Authors:  K D Bloch; G Filippov; L S Sanchez; M Nakane; S M de la Monte
Journal:  Am J Physiol       Date:  1997-03

8.  Ligating the ductus arteriosus before birth causes persistent pulmonary hypertension in the newborn lamb.

Authors:  F C Morin
Journal:  Pediatr Res       Date:  1989-03       Impact factor: 3.756

9.  Coordinated regulation of genes of the nitric oxide and endothelin pathways during the development of pulmonary hypertension in fetal lambs.

Authors:  S M Black; M J Johengen; S J Soifer
Journal:  Pediatr Res       Date:  1998-12       Impact factor: 3.756

10.  Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity.

Authors:  K A Hanson; J W Ziegler; S D Rybalkin; J W Miller; S H Abman; W R Clarke
Journal:  Am J Physiol       Date:  1998-11
View more
  33 in total

1.  Cross talk between NADPH oxidase and autophagy in pulmonary artery endothelial cells with intrauterine persistent pulmonary hypertension.

Authors:  Ru-Jeng Teng; Jianhai Du; Scott Welak; Tongju Guan; Annie Eis; Yang Shi; Girija G Konduri
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-13       Impact factor: 5.464

Review 2.  The role of genetic polymorphisms in antioxidant enzymes and potential antioxidant therapies in neonatal lung disease.

Authors:  Carlo Dani; Chiara Poggi
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

Review 3.  Therapies that enhance pulmonary vascular NO-signaling in the neonate.

Authors:  Julie Dillard; Marta Perez; Bernadette Chen
Journal:  Nitric Oxide       Date:  2019-12-20       Impact factor: 4.427

Review 4.  Role of reactive oxygen species in neonatal pulmonary vascular disease.

Authors:  Stephen Wedgwood; Robin H Steinhorn
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

Review 5.  Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents.

Authors:  Nicolas F M Porta; Robin H Steinhorn
Journal:  Clin Perinatol       Date:  2012-03       Impact factor: 3.430

Review 6.  Therapeutic approaches using nitric oxide in infants and children.

Authors:  Robin H Steinhorn
Journal:  Free Radic Biol Med       Date:  2011-01-13       Impact factor: 7.376

Review 7.  Pharmacotherapy for pulmonary hypertension.

Authors:  Robin H Steinhorn
Journal:  Pediatr Clin North Am       Date:  2012-08-26       Impact factor: 3.278

Review 8.  Endothelial and Smooth Muscle Cell Interactions in the Pathobiology of Pulmonary Hypertension.

Authors:  Yuansheng Gao; Tianji Chen; J Usha Raj
Journal:  Am J Respir Cell Mol Biol       Date:  2016-04       Impact factor: 6.914

9.  Isolation of pulmonary artery smooth muscle cells from neonatal mice.

Authors:  Keng Jin Lee; Lyubov Czech; Gregory B Waypa; Kathryn N Farrow
Journal:  J Vis Exp       Date:  2013-10-19       Impact factor: 1.355

Review 10.  Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide.

Authors:  Satyan Lakshminrusimha; Bobby Mathew; Corinne L Leach
Journal:  Semin Perinatol       Date:  2016-01-14       Impact factor: 3.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.